JOAQUÍN MARÍA CAMPOS ROSA-rekin lankidetzan egindako argitalpenak (22)

2023

  1. Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme

    Purinergic Signalling

2021

  1. Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 36, Núm. 1, pp. 1553-1563

  2. Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: Preclinical evaluation in glioblastoma

    Nanomedicine, Vol. 16, Núm. 23, pp. 2095-2115

  3. New insights into cytotoxic mechanisms of bozepinib against glioblastoma

    European Journal of Pharmaceutical Sciences, Vol. 162

2018

  1. The teaching team of experienced and beginner professors contributes to the continuous improvement of the teaching in the University of Granada

    EDULEARN18 Proceedings: 10th International Conference on Education and New Learning Technology (July 2nd-4th, 2018, Palma, Spain)

2017

  1. 1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds

    Future Medicinal Chemistry, Vol. 9, Núm. 11, pp. 1129-1140

  2. Synthesis of 1,4-benzoxathiin-9H-purine derivatives as antiproliferative agents

    Targets in Heterocyclic Systems, Vol. 21, pp. 372-388

2014

  1. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound

    Oncotarget, Vol. 5, Núm. 11, pp. 3590-3606

2013

  1. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence

    Drug Design, Development and Therapy, Vol. 7, pp. 1301-1313

2011

  1. New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 1, pp. 249-258

  2. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors

    Current Medicinal Chemistry, Vol. 18, Núm. 7, pp. 943-963

  3. Syntheses of 2,3-dihydro-1,4-benzodioxins and bioisosteres as structural motifs for biologically active compounds

    Current Organic Chemistry, Vol. 15, Núm. 6, pp. 869-887

2010

  1. Neighboring-group participation involving the oxygen atom of the O,O- or O,N-acetal functional groups

    Current Organic Chemistry, Vol. 14, Núm. 14, pp. 1461-1477

  2. Synthesis of purine derivatives as scaffolds for a diversity of biological activities

    Current Organic Chemistry, Vol. 14, Núm. 20, pp. 2463-2482

2009

  1. Homochiral drugs: A demanding tendency of the pharmaceutical industry

    Current Medicinal Chemistry, Vol. 16, Núm. 16, pp. 2064-2074

2008

  1. Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines

    Current Medicinal Chemistry, Vol. 15, Núm. 25, pp. 2614-2631

  2. From 5-fluorouracil acyclonucleosides to benzo-fused six- and seven-membered rings linked to pyrimidine and purine bases: The shift from differentiating anticancer agents to apoptotic inducers

    Expert Opinion on Drug Discovery, Vol. 3, Núm. 10, pp. 1223-1235

  3. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

2007

  1. 1H and 13C NMR studies of 2-functionalized 5-(methylsulfonyl)-1-phenyl-1H-indoles

    Magnetic Resonance in Chemistry, Vol. 45, Núm. 2, pp. 185-188

  2. Design, syntheses, biological evaluation, and docking studies of 2-substituted 5-methylsulfonyl-1-phenyl-1H-indoles: Potent and selective in vitro cyclooxygenase-2 inhibitors

    ChemMedChem, Vol. 2, Núm. 1, pp. 88-100